Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
Status:
Completed
Trial end date:
2016-08-18
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of sirolimus when given together
with cisplatin and gemcitabine hydrochloride and to see how well they work in treating
patients with bladder cancer. Biological therapies, such as sirolimus, may stimulate or
suppress the immune system in different ways and stop tumor cells from growing. Drugs used in
chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving sirolimus together with cisplatin and gemcitabine
hydrochloride may be an effective treatment for bladder cancer.